Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B

(American Association for Cancer Research) Responses to tamoxifen were significantly prolonged by reducing levels of the enzyme APOBEC3B in preclinical models of estrogen receptor-positive breast cancer and significantly shortened by increasing levels of APOBEC3B, suggesting that APOBEC3B drives resistance to tamoxifen, according to data presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news